Wordt geladen...
Secukinumab in the treatment of psoriasis: patient selection and perspectives
Secukinumab is a human monoclonal antibody targeting IL-17A that has been approved for three indications: moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. In Phase III clinical trials for each of these three indications, secukinumab has proven to be both highly e...
Bewaard in:
| Gepubliceerd in: | Psoriasis (Auckl) |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Dove Medical Press
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6202001/ https://ncbi.nlm.nih.gov/pubmed/30425963 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PTT.S146004 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|